MLAB

Mesa Laboratories Inc

Add to Watchlist

Advanced Chart

75.620

+1.29(1.736%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

75.630

Open

74.130

VWAP

74.86

Vol

61.85K

Mkt Cap

416.02M

Low

73.960

Amount

4.63M

EV/EBITDA(TTM)

13.46

Total Shares

5.39M

566.65M

EV/OCF(TTM)

12.11

P/S(TTM)

1.71

Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q3

FY2026Q2

FY2026Q1

65.07M

+3.54%

61.03M

+5.53%

60.57M

+4.12%

Estimates Revision

The market is revising Upward the revenue expectations for Mesa Laboratories, Inc. (MLAB) for FY2026, with the revenue forecasts being adjusted by 0.44% over the past three months. During the same period, the stock price has changed by -35.43%.

Revenue Estimates for FY2026

Revise Upward

+0.44%

In Past 3 Month

EPS Estimates for FY2026

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-35.43%

In Past 3 Month

1 Analyst Rating

32.24% Upside

Wall Street analysts forecast MLAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLAB is 100.00 USD with a low forecast of 100.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

0 Hold

1 Sell

Moderate Sell

32.24% Upside

Current: 75.620

Low

100.00

Averages

100.00

High

100.00

32.24% Upside

Current: 75.620

Low

100.00

Averages

100.00

High

100.00

Wells Fargo

Brandon Couillard

Underweight

downgrade

$120 -> $100

2025-05-30

Reason

Wells Fargo

Brandon Couillard

Price Target

$120 -> $100

2025-05-30

downgrade

Underweight

Reason

Wells Fargo analyst Brandon Couillard lowered the firm's price target on Mesa Labs to $100 from $120 and keeps an Underweight rating on the shares. The firm notes Q4 revenues were in line, but adjusted EBITDA missed by about $2M, driven by higher-than-expected bonus accrual. Shares traded sharply lower, which Wells attributes to weak Q4 margins.

Evercore ISI Group

Vijay Kumar

Buy

Maintains

$120 → $160

2024-10-01

Reason

Evercore ISI Group

Vijay Kumar

Price Target

$120 → $160

2024-10-01

Maintains

Buy

Reason

Wells Fargo

Brandon Couillard

Sell

Initiates

$120

2024-08-27

Reason

Wells Fargo

Brandon Couillard

Price Target

$120

2024-08-27

Initiates

Sell

Reason

Evercore ISI Group

Vijay Kumar

Buy

Maintains

$106 → $120

2024-08-06

Reason

Evercore ISI Group

Vijay Kumar

Price Target

$106 → $120

2024-08-06

Maintains

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Mesa Laboratories Inc (MLAB.O) is 42.39, compared to its 5-year average forward P/E of 31.08. For a more detailed relative valuation and DCF analysis to assess Mesa Laboratories Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

31.08

Current PE

42.39

Overvalued PE

45.96

Undervalued PE

16.20

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

21.30

Current EV/EBITDA

9.74

Overvalued EV/EBITDA

28.36

Undervalued EV/EBITDA

14.25

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

5.00

Current PS

1.63

Overvalued PS

7.74

Undervalued PS

2.26